MENRIUM 5-4
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MENRIUM 5-4 (MENRIUM 5-4).
Combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an anticholinergic that blocks muscarinic acetylcholine receptors.
| Metabolism | Chlordiazepoxide: Hepatic via CYP3A4 and CYP2C19 to active metabolites (desmethylchlordiazepoxide, demoxepam); Clidinium: Hepatic, primarily oxidative pathways. |
| Excretion | Chlordiazepoxide: Renal excretion of unchanged drug (<1%) and conjugates (60-70%); fecal excretion (30-40%). Clidinium: Primarily renal elimination as unchanged drug and metabolites (50-70%), with biliary/fecal excretion (30-50%). |
| Half-life | Chlordiazepoxide: Terminal half-life 5-30 hours (mean 10 hours), extended to 30-60 hours in elderly or hepatic impairment. Clidinium: Terminal half-life approximately 1-2 hours due to rapid clearance. |
| Protein binding | Chlordiazepoxide: 96-98% bound to albumin. Clidinium: Approximately 50% bound to plasma proteins. |
| Volume of Distribution | Chlordiazepoxide: 0.26 L/kg. Clidinium: 0.5 L/kg. |
| Bioavailability | Chlordiazepoxide oral: 100% (complete). Clidinium oral: 5-30% (low due to first-pass metabolism, variable). |
| Onset of Action | Chlordiazepoxide oral: 30-60 minutes (anxiolytic). Clidinium oral: 1-2 hours (anticholinergic). |
| Duration of Action | Chlordiazepoxide: 6-8 hours (anxiolytic), up to 24 hours with accumulation. Clidinium: 3-4 hours (antispasmodic), requires multiple daily dosing. |
| Molecular Weight | Chlordiazepoxide: 299.76 Da; Clidinium bromide: 432.2 Da. Note: Menrium 5-4 is a combination product; molecular weight of chlordiazepoxide is 299.76 and clidinium bromide is 432.2. |
1 tablet (chlordiazepoxide 5 mg / clinidium bromide 2.5 mg) orally 3 to 4 times daily before meals and at bedtime. Maximum dose: 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: administer 50% of usual dose. GFR <30 mL/min: avoid use due to accumulation of chlordiazepoxide active metabolites. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: contraindicated due to impaired chlordiazepoxide metabolism. |
| Pediatric use | Not recommended for use in children due to lack of safety and efficacy data. |
| Geriatric use | Initial dose: 1 tablet (chlordiazepoxide 5 mg / clinidium bromide 2.5 mg) orally 2 times daily; increase cautiously. Avoid use in frail elderly due to anticholinergic effects and fall risk. |
| 1st trimester | Avoid; contains chlordiazepoxide (benzodiazepine) which is associated with risk of congenital malformations, especially oral clefts, when used during first trimester. Also contains clidinium bromide, an anticholinergic, with limited human data; animal studies show some teratogenicity. |
| 2nd trimester | Use only if clearly needed; benzodiazepine exposure may cause adverse effects on fetal growth and neurodevelopment. Anticholinergic effects may be teratogenic in animal studies. |
| 3rd trimester | Avoid; chronic maternal benzodiazepine use can lead to neonatal withdrawal syndrome, floppy infant syndrome, and respiratory depression. Anticholinergic effects may cause neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for MENRIUM 5-4 (MENRIUM 5-4).
| Placental transfer | Chlordiazepoxide and its metabolite readily cross the placenta. Clidinium bromide likely crosses placenta to a lesser extent due to quaternary ammonium structure. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to chlordiazepoxide, clidinium, or any componentNarrow-angle glaucomaObstructive uropathy (e.g., bladder neck obstruction, prostatic hypertrophy)Myasthenia gravisSevere hepatic impairmentSevere renal impairmentConcurrent use with CYP3A4 inducers/inhibitors causing significant interaction
| Precautions | Risk of dependence and withdrawal reactions with prolonged use, May impair cognitive and motor functions, Caution in elderly, debilitated patients, and those with hepatic or renal impairment, Concomitant use with opioids may cause profound sedation, respiratory depression, coma, and death |
| Food/Dietary | Avoid alcohol. No specific food interactions; but high-fat meals may delay absorption. Maintain adequate hydration to counteract anticholinergic effects. |
Loading safety data…
| Chlordiazepoxide and its active metabolite (nordiazepam) are excreted into breast milk; accumulation in infants may occur with long-term use. Clidinium bromide is poorly absorbed orally but may suppress lactation via anticholinergic effect. Use only if essential, monitor infant for sedation, feeding difficulties, and weight loss. |
| Lactation Rating | L3 (Moderately Safe) - Use caution |
| Teratogenic Risk | First trimester: Increased risk of neural tube defects and congenital heart malformations due to chlordiazepoxide (benzodiazepine) exposure. Second and third trimesters: Risk of fetal benzodiazepine syndrome, including hypotonia, respiratory depression, and withdrawal symptoms in neonates. The estrogen component (estriol) may cause feminization of male fetuses and virilization of female fetuses if high doses are used. |
| Fetal Monitoring | Monitor maternal blood pressure, liver function, and signs of fluid retention. Fetal ultrasound for anatomy and growth in second trimester. Nonstress test or biophysical profile in third trimester. Monitor neonate for respiratory depression, hypotonia, and withdrawal symptoms (irritability, tremors) for 48–72 hours postpartum. |
| Fertility Effects | Chlordiazepoxide may impair fertility in males and females due to effects on hormone regulation (elevated prolactin, menstrual irregularities, decreased libido). Estriol, as an estrogen, may suppress ovulation and affect endometrial receptivity. |
| Clinical Pearls | Menrium 5-4 (chlordiazepoxide 5 mg + clidinium 4 mg) is used for peptic ulcer and irritable bowel syndrome. Chlordiazepoxide may cause dependence; avoid abrupt withdrawal. Clidinium is an anticholinergic; contraindicated in glaucoma, myasthenia gravis, obstructive uropathy. Use cautiously in elderly due to fall risk and cognitive impairment. |
| Patient Advice | Avoid alcohol and CNS depressants. · Do not drive or operate machinery until you know how this medication affects you. · Report symptoms like difficulty urinating, blurred vision, or constipation. · Do not stop suddenly; taper under medical supervision to avoid withdrawal. · Take as directed; anticholinergic effects may cause dry mouth—sugarless gum or hard candy may help. |